Tiziana Life Sciences LtdNASDAQ:TLSANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8350/ 2
- Ask / Lots0.8500/ 15
- Open / Previous Close0.0000 / 0.8000
- Day Range---
- 52 Week Range
- Volume875
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 879 | 0.76 |
| 09:39 ET | 300 | 0.8 |
| 09:52 ET | 315 | 0.7999 |
| 09:57 ET | 19967 | 0.8 |
| 10:01 ET | 2030 | 0.8 |
| 10:12 ET | 500 | 0.770001 |
| 10:46 ET | 500 | 0.7867 |
| 10:50 ET | 6137 | 0.7999 |
| 10:51 ET | 2500 | 0.7946 |
| 10:55 ET | 201 | 0.776001 |
| 11:09 ET | 290 | 0.76 |
| 11:13 ET | 221 | 0.798 |
| 11:20 ET | 2100 | 0.7809 |
| 12:00 ET | 1400 | 0.78 |
| 12:05 ET | 300 | 0.7801 |
| 12:16 ET | 228 | 0.79 |
| 12:18 ET | 309 | 0.7802 |
| 12:34 ET | 700 | 0.79 |
| 12:57 ET | 2502 | 0.78 |
| 01:12 ET | 1400 | 0.79 |
| 01:30 ET | 1777 | 0.78 |
| 01:48 ET | 8000 | 0.7801 |
| 02:42 ET | 128 | 0.799 |
| 03:05 ET | 37882 | 0.815 |
| 03:23 ET | 100 | 0.801 |
| 03:25 ET | 200 | 0.8008 |
| 03:43 ET | 100 | 0.8008 |
| 03:50 ET | 1000 | 0.8008 |
| 03:56 ET | 20300 | 0.83 |
| 03:57 ET | 1974 | 0.8 |
Jun 11, 2024
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises, from 8:45AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:45AM ET on Tuesday Jun 11, 2024 by Dow JonesFDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
Jun 6, 2024
Jun 4, 2024
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab, from 9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
May 30, 2024
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research, from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 82.5M | -5.3x | --- |
DiaMedica Therapeutics Inc | 82.0M | -3.9x | --- |
PMV Pharmaceuticals Inc | 83.1M | -1.2x | --- |
Vor Biopharma Inc | 81.2M | -0.7x | --- |
Verastem Inc | 80.0M | -0.7x | --- |
Allovir Inc | 85.5M | -0.4x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer, Chief Scientific Officer, Executive Director
- Kunwar Shailubhai
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $82.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 103.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.45 |
EPS | $-0.15 |
Book Value | $0.19 |
P/E Ratio | -5.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
